🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,187 results for “Takeda” Clear

  1. MLN2480

    Takeda

    Melanoma

    phase 1 small molecule completed

    1 trial

  2. MLN3126

    Takeda

    Healthy Volunteers

    phase 1 small molecule terminated

    1 trial

  3. MLN3126

    Takeda

    Safety

    phase 1 small molecule terminated

    1 trial

  4. MLN4924

    Takeda

    Acute Myelogenous Leukemia

    phase 1 small molecule completed

    1 trial

  5. MLN4924

    Takeda

    Advanced Solid Tumors

    phase 1 small molecule completed

    1 trial

  6. MLN4924

    Takeda

    Solid Tumors

    phase 1 small molecule completed

    1 trial

  7. MLN7243

    Takeda

    Advanced Malignant Solid Tumors

    phase 1 small molecule terminated

    1 trial

  8. MT203 80 mg or matching Placebo

    Takeda

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  9. MVC-101

    Takeda

    Solid Tumour

    phase 1 mab terminated

    1 trial

  10. Maribavir

    Takeda

    Healthy Volunteers

    phase 1 small molecule completed

    2 trials

  11. Maribavir (400 mg)

    Takeda

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  12. Maribavir Commercial Tablet Formulation

    Takeda

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  13. Mesalamine

    Takeda

    Healthy

    phase 1 small molecule completed

    1 trial

  14. Metronidazole + MMX Mesalazine/mesalamine placebo

    Takeda

    Healthy

    phase 1 small molecule completed

    1 trial

  15. Mezagitamab

    Takeda

    Kidney Disease

    phase 1 small molecule completed

    2 trials

  16. Midazolam

    Takeda

    Carcinoma, Advanced ALK+ or ROS1+Non-Small-Cell Lung, Neoplasm, Advanced ALK+ or ROS1+Solid Tumors

    phase 1 small molecule completed

    1 trial

  17. Midazolam

    Takeda

    Carcinoma, Non-Small-Cell Lung

    phase 1 small molecule completed

    1 trial

  18. Midazolam

    Takeda

    Healthy

    phase 1 small molecule completed

    1 trial

  19. Midazolam

    Takeda

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  20. Mobocertinib

    Takeda

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  21. Mobocertinib

    Takeda

    Renal Impairment

    phase 1 small molecule completed

    1 trial

  22. Mobocertinib

    Takeda

    Non-Small Cell Lung Cancer

    phase 1 small molecule active

    1 trial

  23. Mobocertinib

    Takeda

    Hepatic Impairment

    phase 1 small molecule completed

    1 trial

  24. Niraparib

    Takeda

    Advanced Solid Tumors

    phase 1 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources